Aripiprazole (Abilify) in Catatonia with Aggression on Lorazepam
Continue lorazepam as the primary treatment for catatonia and add aripiprazole 10-15 mg daily orally for management of aggression and psychotic symptoms, while monitoring closely for increased sedation and orthostatic hypotension from the combination.
Treatment Approach
Continue Lorazepam for Catatonia
Lorazepam remains the first-line treatment for catatonia with strong evidence supporting its efficacy 1. The patient should continue current lorazepam dosing, as benzodiazepines show an overall effect of -11.88 points on the Bush Francis Catatonia Rating Scale with large effect size (Cohen's d = -3.15) 1. There is no maximum dose for lorazepam in catatonia—continue titrating until side effects occur or sufficient symptom improvement is achieved 2.
Add Aripiprazole for Aggression and Psychosis
Initiation: Start aripiprazole at 10-15 mg once daily without regard to meals 3. The FDA label specifies this as the recommended starting and target dose for schizophrenia and psychotic symptoms 3.
Rationale for combination:
- Aripiprazole has demonstrated rapid efficacy in resolving catatonic symptoms in multiple case reports, particularly when combined with lorazepam 4, 5, 6
- The drug's unique receptor profile—acting as both a D2 receptor antagonist and partial agonist depending on cellular milieu—provides efficacy with a favorable side effect profile compared to other antipsychotics 6
- Aripiprazole enhances GABA transmission in certain brain areas, which may complement lorazepam's GABAergic mechanism 6
Critical Drug Interaction Warning
Monitor intensively for enhanced sedation and orthostatic hypotension when combining aripiprazole with lorazepam 3. The FDA label explicitly warns that "the intensity of sedation was greater with the combination of oral aripiprazole and lorazepam as compared to that observed with aripiprazole alone. The orthostatic hypotension observed was greater with the combination as compared to that observed with lorazepam alone" 3.
Specific monitoring:
- Check blood pressure sitting and standing at baseline and after each dose adjustment
- Assess sedation level regularly
- Adjust doses accordingly if excessive sedation or hypotension develops 3
Dosing Considerations
No dose adjustment needed: The FDA label confirms that no dosage adjustment of aripiprazole is required when administered concomitantly with lorazepam from a pharmacokinetic standpoint 3. However, the pharmacodynamic interaction (increased sedation/hypotension) requires clinical monitoring.
Titration if needed: If 10-15 mg daily is insufficient for aggression control after 2 weeks (time to steady state), increase in 5 mg increments up to maximum 30 mg daily 3. However, doses above 15 mg/day have not shown superior efficacy in trials 3.
Alternative Considerations
If aripiprazole is not tolerated or effective, consider:
- Haloperidol 0.5-2 mg for severe agitation, though this carries higher risk of extrapyramidal symptoms 7
- Ziprasidone IM 20 mg for acute agitation episodes, which has shown lower movement disorder risk 7
- Electroconvulsive therapy should be pursued if partial or no response to lorazepam, regardless of ECT accessibility 2
Common Pitfalls to Avoid
- Do not use typical antipsychotics as first-line in catatonia due to risk of worsening symptoms and neuroleptic malignant syndrome
- Do not underdose lorazepam—there is no maximum dose in catatonia treatment 2
- Do not delay ECT if lorazepam response is inadequate; other agents should not delay pursuit of ECT 2
- Avoid anticholinergic agents (like benztropine) for extrapyramidal symptoms in this context, as they may worsen catatonia 8